Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email mava@mava.org.
 

 

Check back regularly for news, coverage, and announcements about MAVA.

  
Here is some sample content

01/13/2015 – New Enterprise Associates is raising a massive $2.5B for its 15th fund

New Enterprise Associates (NEA), one of the largest venture capital firms around, is raising its 15th fund.

01/13/2015 – Cortendo to raise up to $27.5 mln in private placement

Cortendo AB has agreed to receive up to $27.5 million in a private placement.

01/13/2015 – Sensory NeuroStimulation Inc. Establishes $1.5 Million Credit Facility With Silicon Valley Bank

Sensory NeuroStimulation, Inc., makers of the Relaxis™ device for treating Restless Legs Syndrome (RLS), has entered into a new credit agreement with Silicon Valley Bank, the company announced today.

01/12/2015 – Cerulean Secures $26MM Facility From Hercules Technology Growth Capital

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting, has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. for a term loan of up to $26.0 million and completed a private placement for $1.0 million of Cerulean common stock with Hercules.

01/09/2015 – Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics

Trevi Therapeutics, Inc., a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender.

01/08/2015 – Welltok Completes $37 Million Funding Round With New Investors

Welltok, developer of the CafeWell Health Optimization Platform, officially closed its most recent funding round of $37 million.

01/08/2015 – Trevi closes $15 mln loan from Solar Capital and Square 1 Bank

Trevi Therapeutics has secured a $15 million senior loan from Solar Capital and Square 1 Bank.

01/08/2015 – Surface Oncology attracts $35 mln Series A

Surface Oncology has secured $35 million in Series A funding.

01/07/2015 – Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin Platform for Cancer Therapeutics

Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding.

01/07/2015 – Vtesse Inc. raises $25M Series A led by NEA

Biotech accelerator Cydan Development Inc. announced Wednesday $25 million in Series A funding to launch Vtesse Inc., which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children.

12   3456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125